Cargando…

PD-L1 and PD-L2 expression in the tumor microenvironment including peritumoral tissue in primary central nervous system lymphoma

BACKGROUND: The prevalence of programmed death-ligand 1 (PD-L1) and PD-L2 expression on tumor cells and tumor-infiltrating immune cells in primary central nervous system lymphoma (PCNSL) remains unclear. In the present study, we analyzed needle biopsy and craniotomy specimens of patients with PCNSL...

Descripción completa

Detalles Bibliográficos
Autores principales: Furuse, Motomasa, Kuwabara, Hiroko, Ikeda, Naokado, Hattori, Yasuhiko, Ichikawa, Tomotsugu, Kagawa, Naoki, Kikuta, Kenichiro, Tamai, Sho, Nakada, Mitsutoshi, Wakabayashi, Toshihiko, Wanibuchi, Masahiko, Kuroiwa, Toshihiko, Hirose, Yoshinobu, Miyatake, Shin-Ichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7132991/
https://www.ncbi.nlm.nih.gov/pubmed/32248797
http://dx.doi.org/10.1186/s12885-020-06755-y
_version_ 1783517542547980288
author Furuse, Motomasa
Kuwabara, Hiroko
Ikeda, Naokado
Hattori, Yasuhiko
Ichikawa, Tomotsugu
Kagawa, Naoki
Kikuta, Kenichiro
Tamai, Sho
Nakada, Mitsutoshi
Wakabayashi, Toshihiko
Wanibuchi, Masahiko
Kuroiwa, Toshihiko
Hirose, Yoshinobu
Miyatake, Shin-Ichi
author_facet Furuse, Motomasa
Kuwabara, Hiroko
Ikeda, Naokado
Hattori, Yasuhiko
Ichikawa, Tomotsugu
Kagawa, Naoki
Kikuta, Kenichiro
Tamai, Sho
Nakada, Mitsutoshi
Wakabayashi, Toshihiko
Wanibuchi, Masahiko
Kuroiwa, Toshihiko
Hirose, Yoshinobu
Miyatake, Shin-Ichi
author_sort Furuse, Motomasa
collection PubMed
description BACKGROUND: The prevalence of programmed death-ligand 1 (PD-L1) and PD-L2 expression on tumor cells and tumor-infiltrating immune cells in primary central nervous system lymphoma (PCNSL) remains unclear. In the present study, we analyzed needle biopsy and craniotomy specimens of patients with PCNSL to compare the PD-L1 and PD-L2 levels in the tumor and surrounding (peritumoral) tissue. We also assessed the correlation between biological factors and the prognostic significance of PD-L1 and PD-L2 expression. METHODS: We retrospectively analyzed the cases of 70 patients histologically diagnosed with PCNSL (diffuse large B-cell lymphoma). Immunohistochemistry for CD20, CD68, PD-L1, and PD-L2 was performed. In cases with specimens taken by craniotomy, the percentages of PD-L1- and PD-L2-positive macrophages were evaluated in both tumor and peritumoral tissue. The Kaplan-Meier method with log-rank test and Cox proportional hazard model were used for survival analysis. RESULTS: The tumor cells expressed little or no PD-L1 and PD-L2, but macrophages expressed PD-L1 and PD-L2 in most of the patients. The median percentage of PD-L2-positive cells was significantly higher among peritumoral macrophages (32.5%; 95% CI: 0–94.6) than intratumoral macrophages (27.5%; 95% CI: 0–81.1, p = 0.0014). There was a significant correlation between the percentages of PD-L2-positive intratumoral macrophages and PD-L2-positive peritumoral macrophages (p = 0.0429), with very low coefficient correlation (ρ = 0.098535). PD-L1 expression on macrophages was significantly associated with biological factors (intratumoral macrophages: better KPS, p = 0.0008; better MSKCC score, p = 0.0103; peritumoral macrophages: low proportion of LDH elevation, p = 0.0064) and longer OS (for intratumoral macrophages: high PD-L1 = 60 months, 95% CI = 30–132.6; low PD-L1 = 24 months, 95% CI = 11–48; p = 0.032; for peritumoral macrophages: high PD-L1 = 60 months, 95% CI = 30.7–NR; low PD-L1 = 14 months, 95% CI = 3–26). PD-L1 expression on peritumoral macrophages was strongly predictive of a favorable outcome (HR = 0.30, 95% CI = 0.12–0.77, p = 0.0129). CONCLUSIONS: Macrophages in intratumoral and peritumoral tissue expressed PD-L1 and PD-L2 at a higher rate than tumor cells. PD-L1 expression, especially on peritumoral macrophages, seems to be an important prognostic factor in PCNSL. Future comprehensive analysis of checkpoint molecules in the tumor microenvironment, including the peritumoral tissue, is warranted.
format Online
Article
Text
id pubmed-7132991
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-71329912020-04-11 PD-L1 and PD-L2 expression in the tumor microenvironment including peritumoral tissue in primary central nervous system lymphoma Furuse, Motomasa Kuwabara, Hiroko Ikeda, Naokado Hattori, Yasuhiko Ichikawa, Tomotsugu Kagawa, Naoki Kikuta, Kenichiro Tamai, Sho Nakada, Mitsutoshi Wakabayashi, Toshihiko Wanibuchi, Masahiko Kuroiwa, Toshihiko Hirose, Yoshinobu Miyatake, Shin-Ichi BMC Cancer Research Article BACKGROUND: The prevalence of programmed death-ligand 1 (PD-L1) and PD-L2 expression on tumor cells and tumor-infiltrating immune cells in primary central nervous system lymphoma (PCNSL) remains unclear. In the present study, we analyzed needle biopsy and craniotomy specimens of patients with PCNSL to compare the PD-L1 and PD-L2 levels in the tumor and surrounding (peritumoral) tissue. We also assessed the correlation between biological factors and the prognostic significance of PD-L1 and PD-L2 expression. METHODS: We retrospectively analyzed the cases of 70 patients histologically diagnosed with PCNSL (diffuse large B-cell lymphoma). Immunohistochemistry for CD20, CD68, PD-L1, and PD-L2 was performed. In cases with specimens taken by craniotomy, the percentages of PD-L1- and PD-L2-positive macrophages were evaluated in both tumor and peritumoral tissue. The Kaplan-Meier method with log-rank test and Cox proportional hazard model were used for survival analysis. RESULTS: The tumor cells expressed little or no PD-L1 and PD-L2, but macrophages expressed PD-L1 and PD-L2 in most of the patients. The median percentage of PD-L2-positive cells was significantly higher among peritumoral macrophages (32.5%; 95% CI: 0–94.6) than intratumoral macrophages (27.5%; 95% CI: 0–81.1, p = 0.0014). There was a significant correlation between the percentages of PD-L2-positive intratumoral macrophages and PD-L2-positive peritumoral macrophages (p = 0.0429), with very low coefficient correlation (ρ = 0.098535). PD-L1 expression on macrophages was significantly associated with biological factors (intratumoral macrophages: better KPS, p = 0.0008; better MSKCC score, p = 0.0103; peritumoral macrophages: low proportion of LDH elevation, p = 0.0064) and longer OS (for intratumoral macrophages: high PD-L1 = 60 months, 95% CI = 30–132.6; low PD-L1 = 24 months, 95% CI = 11–48; p = 0.032; for peritumoral macrophages: high PD-L1 = 60 months, 95% CI = 30.7–NR; low PD-L1 = 14 months, 95% CI = 3–26). PD-L1 expression on peritumoral macrophages was strongly predictive of a favorable outcome (HR = 0.30, 95% CI = 0.12–0.77, p = 0.0129). CONCLUSIONS: Macrophages in intratumoral and peritumoral tissue expressed PD-L1 and PD-L2 at a higher rate than tumor cells. PD-L1 expression, especially on peritumoral macrophages, seems to be an important prognostic factor in PCNSL. Future comprehensive analysis of checkpoint molecules in the tumor microenvironment, including the peritumoral tissue, is warranted. BioMed Central 2020-04-05 /pmc/articles/PMC7132991/ /pubmed/32248797 http://dx.doi.org/10.1186/s12885-020-06755-y Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Furuse, Motomasa
Kuwabara, Hiroko
Ikeda, Naokado
Hattori, Yasuhiko
Ichikawa, Tomotsugu
Kagawa, Naoki
Kikuta, Kenichiro
Tamai, Sho
Nakada, Mitsutoshi
Wakabayashi, Toshihiko
Wanibuchi, Masahiko
Kuroiwa, Toshihiko
Hirose, Yoshinobu
Miyatake, Shin-Ichi
PD-L1 and PD-L2 expression in the tumor microenvironment including peritumoral tissue in primary central nervous system lymphoma
title PD-L1 and PD-L2 expression in the tumor microenvironment including peritumoral tissue in primary central nervous system lymphoma
title_full PD-L1 and PD-L2 expression in the tumor microenvironment including peritumoral tissue in primary central nervous system lymphoma
title_fullStr PD-L1 and PD-L2 expression in the tumor microenvironment including peritumoral tissue in primary central nervous system lymphoma
title_full_unstemmed PD-L1 and PD-L2 expression in the tumor microenvironment including peritumoral tissue in primary central nervous system lymphoma
title_short PD-L1 and PD-L2 expression in the tumor microenvironment including peritumoral tissue in primary central nervous system lymphoma
title_sort pd-l1 and pd-l2 expression in the tumor microenvironment including peritumoral tissue in primary central nervous system lymphoma
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7132991/
https://www.ncbi.nlm.nih.gov/pubmed/32248797
http://dx.doi.org/10.1186/s12885-020-06755-y
work_keys_str_mv AT furusemotomasa pdl1andpdl2expressioninthetumormicroenvironmentincludingperitumoraltissueinprimarycentralnervoussystemlymphoma
AT kuwabarahiroko pdl1andpdl2expressioninthetumormicroenvironmentincludingperitumoraltissueinprimarycentralnervoussystemlymphoma
AT ikedanaokado pdl1andpdl2expressioninthetumormicroenvironmentincludingperitumoraltissueinprimarycentralnervoussystemlymphoma
AT hattoriyasuhiko pdl1andpdl2expressioninthetumormicroenvironmentincludingperitumoraltissueinprimarycentralnervoussystemlymphoma
AT ichikawatomotsugu pdl1andpdl2expressioninthetumormicroenvironmentincludingperitumoraltissueinprimarycentralnervoussystemlymphoma
AT kagawanaoki pdl1andpdl2expressioninthetumormicroenvironmentincludingperitumoraltissueinprimarycentralnervoussystemlymphoma
AT kikutakenichiro pdl1andpdl2expressioninthetumormicroenvironmentincludingperitumoraltissueinprimarycentralnervoussystemlymphoma
AT tamaisho pdl1andpdl2expressioninthetumormicroenvironmentincludingperitumoraltissueinprimarycentralnervoussystemlymphoma
AT nakadamitsutoshi pdl1andpdl2expressioninthetumormicroenvironmentincludingperitumoraltissueinprimarycentralnervoussystemlymphoma
AT wakabayashitoshihiko pdl1andpdl2expressioninthetumormicroenvironmentincludingperitumoraltissueinprimarycentralnervoussystemlymphoma
AT wanibuchimasahiko pdl1andpdl2expressioninthetumormicroenvironmentincludingperitumoraltissueinprimarycentralnervoussystemlymphoma
AT kuroiwatoshihiko pdl1andpdl2expressioninthetumormicroenvironmentincludingperitumoraltissueinprimarycentralnervoussystemlymphoma
AT hiroseyoshinobu pdl1andpdl2expressioninthetumormicroenvironmentincludingperitumoraltissueinprimarycentralnervoussystemlymphoma
AT miyatakeshinichi pdl1andpdl2expressioninthetumormicroenvironmentincludingperitumoraltissueinprimarycentralnervoussystemlymphoma